101 related articles for article (PubMed ID: 1931460)
1. Podophyllotoxin derivatives.
D'Incalci M; Garattini S
Cancer Chemother Biol Response Modif; 1991; 12():75-81. PubMed ID: 1931460
[No Abstract] [Full Text] [Related]
2. Podophyllotoxin derivatives VP-16 and VM-26.
D'Incalci M; Garattini S
Cancer Chemother Biol Response Modif; 1987; 9():67-70. PubMed ID: 3079416
[No Abstract] [Full Text] [Related]
3. Podophyllotoxin derivatives VP-16 and VM-26.
D'Incalci M; Garattini S
Cancer Chemother Biol Response Modif; 1988; 10():57-63. PubMed ID: 3079398
[No Abstract] [Full Text] [Related]
4. The podophyllotoxin derivatives VP16-213 and VM26.
Issell BF
Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593
[TBL] [Abstract][Full Text] [Related]
5. Podophyllotoxin derivatives.
D'Incalci M; Garattini S
Cancer Chemother Biol Response Modif; 1992; 13():75-82. PubMed ID: 1389926
[No Abstract] [Full Text] [Related]
6. [New antineoplastic drugs of the podophyllotoxin derivative group].
Robak T; Płuzańska A
Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
[No Abstract] [Full Text] [Related]
7. Teniposide: a review of 12 years of experience.
O'Dwyer PJ; Alonso MT; Leyland-Jones B; Marsoni S
Cancer Treat Rep; 1984 Dec; 68(12):1455-66. PubMed ID: 6391663
[No Abstract] [Full Text] [Related]
8. New anticancer drug class.
Fuerst ML
JAMA; 1983 Mar; 249(12):1539, 1543. PubMed ID: 6827733
[No Abstract] [Full Text] [Related]
9. DNA topoisomerase II inhibitors.
IARC Monogr Eval Carcinog Risks Hum; 2000; 76():175-344. PubMed ID: 11000976
[No Abstract] [Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins.
McLeod HL; Evans WE
Cancer Surv; 1993; 17():253-68. PubMed ID: 8137343
[TBL] [Abstract][Full Text] [Related]
11. Secondary acute promyelocytic leukemia in a child treated with epipodophyllotoxins.
Lopez-Andrew JA; Ferrís J; Verdeguer A; Esquembre C; Senent ML; Castel V
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):384-6. PubMed ID: 7978063
[No Abstract] [Full Text] [Related]
12. Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.
Gupta RS
Cancer Res; 1983 Apr; 43(4):1568-74. PubMed ID: 6831403
[No Abstract] [Full Text] [Related]
13. The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.
Nissen NI; Dombernowsky P; Hansen HH; Pedersen AG
Recent Results Cancer Res; 1980; 74():98-106. PubMed ID: 7003663
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies in relation to drug action.
Muggia FM; McVie G
NCI Monogr; 1987; (4):129-33. PubMed ID: 2819724
[No Abstract] [Full Text] [Related]
15. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
16. Etoposide and teniposide in the treatment of acute leukemia.
Björkholm M
Med Oncol Tumor Pharmacother; 1990; 7(1):3-10. PubMed ID: 2187120
[TBL] [Abstract][Full Text] [Related]
17. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.
Roed H; Vindelov LL; Christensen IJ; Spang-Thomsen M; Hansen HH
Cancer Chemother Pharmacol; 1987; 19(1):16-20. PubMed ID: 3815721
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of VM-26 in adult malignancies.
Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
[No Abstract] [Full Text] [Related]
19. The epipodophyllotoxin derivatives VM26 and VP16: experimental and clinical aspects.
Dombernowsky P; Hansen HH
Eur J Haematol Suppl; 1988; 48():49-57. PubMed ID: 3073960
[No Abstract] [Full Text] [Related]
20. VM 26 and VP 16-213: a comparative analysis.
Rozencweig M; Von Hoff DD; Henney JE; Muggia FM
Cancer; 1977 Jul; 40(1):334-42. PubMed ID: 328129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
